Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Synthesis, identification and in vivo studies of tumor-targeting agent peptide doxorubicin (PDOX) to treat peritoneal carcinomatosis of gastric cancer with similar efficacy but reduced toxicity.

Tang L, Duan R, Zhong YJ, Firestone RA, Hong YP, Li JG, Xin YC, Wu HL, Li Y.

Mol Cancer. 2014 Mar 3;13:44. doi: 10.1186/1476-4598-13-44.

2.

Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: an experimental study.

Shao LH, Liu SP, Hou JX, Zhang YH, Peng CW, Zhong YJ, Liu X, Liu XL, Hong YP, Firestone RA, Li Y.

Cancer. 2012 Jun 1;118(11):2986-96. doi: 10.1002/cncr.26596. Epub 2011 Oct 17.

3.

Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study.

Wang Q, Zhong YJ, Yuan JP, Shao LH, Zhang J, Tang L, Liu SP, Hong YP, Firestone RA, Li Y.

J Transl Med. 2013 Aug 21;11:192. doi: 10.1186/1479-5876-11-192.

4.
5.

Anti-cancer effects of novel doxorubicin prodrug PDOX in MCF-7 breast cancer cells.

Zhang J, He L, Geng XF, Firestone RA, Hong YP, Li Y.

J Huazhong Univ Sci Technolog Med Sci. 2014 Aug;34(4):521-8. doi: 10.1007/s11596-014-1309-x. Epub 2014 Aug 19.

PMID:
25135721
6.

Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer.

Zhang J, Yuan JP, Wang Q, Shao LH, Liu SP, Firestone RA, Hong YP, Li JG, Xin YC, Li Y.

Oncotarget. 2017 Dec 14;9(2):1957-1968. doi: 10.18632/oncotarget.23319. eCollection 2018 Jan 5.

7.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial.

Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y.

Ann Surg Oncol. 2011 Jun;18(6):1575-81. doi: 10.1245/s10434-011-1631-5. Epub 2011 Mar 23.

8.

Anticancer effects of Ac‑Phe‑Lys‑PABC‑doxorubicin via mitochondria‑centered apoptosis involving reactive oxidative stress and the ERK1/2 signaling pathway in MGC‑803 cells.

Zhong YJ, Liu SP, Firestone RA, Hong YP, Li Y.

Oncol Rep. 2013 Oct;30(4):1681-6. doi: 10.3892/or.2013.2629. Epub 2013 Jul 19.

PMID:
23877402
9.

Perioperative systemic chemotherapy in peritoneal carcinomatosis of lymph node positive colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Kuijpers AM, Mehta AM, Boot H, van Leerdam ME, Hauptmann M, Aalbers AG, Verwaal VJ.

Ann Oncol. 2014 Apr;25(4):864-9. doi: 10.1093/annonc/mdu031.

PMID:
24667719
10.

Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy.

Hultman B, Lind P, Glimelius B, Sundbom M, Nygren P, Haglund U, Mahteme H.

Acta Oncol. 2013 May;52(4):824-30. doi: 10.3109/0284186X.2012.702925. Epub 2012 Sep 14.

PMID:
22974074
11.

Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.

Sardi A, Jimenez WA, Nieroda C, Sittig M, Macdonald R, Gushchin V.

Eur J Surg Oncol. 2013 Nov;39(11):1207-13. doi: 10.1016/j.ejso.2013.08.017. Epub 2013 Sep 2.

PMID:
24007834
12.

Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale.

Roviello F, Caruso S, Neri A, Marrelli D.

Eur J Surg Oncol. 2013 Dec;39(12):1309-16. doi: 10.1016/j.ejso.2013.10.010. Epub 2013 Oct 23. Review.

PMID:
24183797
13.

Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.

Wu X, Li Z, Li Z, Jia Y, Shan F, Ji X, Bu Z, Zhang L, Wu A, Ji J.

J Surg Oncol. 2015 Jun;111(7):840-7. doi: 10.1002/jso.23889. Epub 2015 Apr 10.

PMID:
25864884
14.

Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands.

Razenberg LG, van Gestel YR, Creemers GJ, Verwaal VJ, Lemmens VE, de Hingh IH.

Eur J Surg Oncol. 2015 Apr;41(4):466-71. doi: 10.1016/j.ejso.2015.01.018. Epub 2015 Jan 29.

PMID:
25680955
15.

Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer.

Colombo PE, Boustta M, Poujol S, Jarlier M, Bressolle F, Teulon I, Ladjemi MZ, Pinguet F, Rouanet P, Vert M.

Gynecol Oncol. 2011 Sep;122(3):632-40. doi: 10.1016/j.ygyno.2011.05.032. Epub 2011 Jun 12.

PMID:
21665252
16.

Peritoneal carcinomatosis from unusual cancer origins: Is there a role for hyperthermic intraperitoneal chemotherapy?

Honoré C, Goéré D, Macovei R, Colace L, Benhaim L, Elias D.

J Visc Surg. 2016 Apr;153(2):101-7. doi: 10.1016/j.jviscsurg.2015.11.010. Epub 2015 Dec 11.

PMID:
26698380
17.

Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study.

Cashin PH, Graf W, Nygren P, Mahteme H.

Eur J Surg Oncol. 2012 Jun;38(6):509-15. doi: 10.1016/j.ejso.2012.03.001. Epub 2012 Apr 3.

PMID:
22475555
18.

Synthesis and Evaluation of a CBZ-AAN-Dox Prodrug and its in vitro Effects on SiHa Cervical Cancer Cells Under Hypoxic Conditions.

Chen H, Liu X, Clayman ES, Shao F, Xiao M, Tian X, Fu W, Zhang C, Ruan B, Zhou P, Liu Z, Wang Y, Rui W.

Chem Biol Drug Des. 2015 Oct;86(4):589-98. doi: 10.1111/cbdd.12525. Epub 2015 Mar 1.

PMID:
25619622
19.

Preliminary results of prophylactic HIPEC in patients with locally advanced gastric cancer.

Graziosi L, Cantarella F, Mingrone E, Gunnellini M, Cavazzoni E, Liberati M, Donini A.

Ann Ital Chir. 2013 Sep-Oct;84(5):551-6.

PMID:
24140896
20.

Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.

Quenet F, Goéré D, Mehta SS, Roca L, Dumont F, Hessissen M, Saint-Aubert B, Elias D.

Ann Surg. 2011 Aug;254(2):294-301. doi: 10.1097/SLA.0b013e3182263933.

PMID:
21772129

Supplemental Content

Support Center